

Freedom of Information Act 2000 – Request Reference FoI/24/365

Drug Treatments

Q1 – How many patients were treated with the following drugs from the following departments (for any disease) from the start of Jan 2024 to the end of Mar 2024?

Please use the latest available 3 months if January to March is not available and specify which 3 months has been used.

Please see the table for the number of drugs issued from the list below for the period 1 January 2024 to 31 March 2024.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)	12	4	32
Adalimumab (Biosimilars)	159	296	288
Apremilast	2	0	2
Bimekizumab	12	0	0
Brodalumab	5	0	0
Certolizumab Pegol	10	0	95
Deucravacitinib	0	0	0
Etanercept (Enbrel)	0	0	24
Etanercept (Biosimilars)	5	0	204
Guselkumab	14	0	4
Infliximab (Remicade)	0	0	3
Infliximab (Biosimilars)	17	132	19
Ixekizumab	13	0	9
Risankizumab	48	15	0
Secukinumab	39	0	35
Tildrakizumab	1	0	0
Ustekinumab	38	124	16
Upadacitinib	13	24	19
Vedolizumab	0	252	1
Filgotinib	0	15	2
Golimumab	0	1	35
Mirikizumab	0	10	0
Ozanimod	0	4	0
Tofacitinib	1	6	8
Baricitinib	9	0	44
Rituximab	1	0	39
Sarilumab	0	0	11
Tocilizumab	0	0	107